Unapproved Peptide Treatments Spread as Safety Concerns Mount
Report describes growing use of peptides sold outside approved channels, raising oversight and patient-safety questions.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 16 10:28 ETSource: Devdiscourse
The wire
- 01Coverage highlights a rise in unapproved peptide treatments amid controversy over their use.
- 02Unregulated peptide use sits outside established safety and efficacy review.
- 03Scope of regulatory response and harms remains unclear from the report.
From the source
Read at news.google.comThe Peptide Controversy: Unapproved Treatments Rise Amid Safety Concerns